Oragenics: 2 New Phase 1 Trials Should Resurrect Investor Sentiment, Driving Upside By 2022Seeking Alpha • 05/09/21
Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 VaccineBusiness Wire • 03/09/21
Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred StockBusiness Wire • 02/12/21
SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in MiceBusiness Wire • 02/02/21
OGEN Stock Alert: 14 Things to Know About Oragenics as Shares Rocket ThursdayInvestorPlace • 01/07/21
Oragenics Enters Into Material Transfer Agreement With Adjuvance Technologies for COVID-19 Vaccine AdjuvantBusiness Wire • 01/07/21
CORRECTING AND REPLACING Oragenics Announces Proposed Underwritten Public OfferingBusiness Wire • 11/19/20
FDA Broadly Supports Oragenics’ Pre-IND Development Program for its SARS-CoV-2 VaccineBusiness Wire • 10/06/20